Influenza

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News

Chickens
#Genetics / genomics #Immunology / Virology & Vaccines #Influenza #Pandemic prevention

Human gene that defends against avian flu discovered

New research has found a key human gene responsible for blocking most avian flu viruses from spilling over into people. The international study into the pandemic potential of avian flu, which is led by scientists at the MRC-University of Glasgow Centre for Virus Research (CVR), identified… Read More

#Editor's Choice #News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

This week in drug discovery (26-30 June)  

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More

#News

AI drug
#Artificial intelligence (AI) #Biopharmaceuticals #Collaboration #Influenza #Poolbeg Pharma

AI-led programme identifies multiple influenza drug targets 

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a breakthrough in its influenza AI Programme with CytoReason.   Poolbeg has been working with CytoReason since March 2022. Poolbeg’s disease progression data from influenza human challenge… Read More

#News

Influenza virus
#Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines #National Institute of Allergy and Infectious Diseases #Phase I trial

mRNA universal influenza vaccine enters clinical trials

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase I trial will test the experimental vaccine,… Read More

#News #Trending News

Influenza
#Acute inflammatory conditions #Biopharmaceuticals #Human trials #Immunomodulators #Infectious diseases #Influenza

New results for severe influenza and inflammatory conditions 

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions.   POLB 001… Read More

#News

Baby on a respirator - RSV
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Covid-19 #Immunology / Virology & Vaccines #Influenza #OneThree #Poolbeg Pharma #Respiratory syncytial virus

AI identifies drug candidates for respiratory syncytial virus

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV.  The AI programme, part of a collaboration between Poolbeg Pharma and OneThree, uses Poolbeg’s RSV human challenge… Read More

#Editor's Choice #News

Vaccine
#Flu vaccine #Influenza #Influenza antigens #World Health Organization

New range of influenza antigens for vaccine development

The Native Antigen Company (part of LGC Clinical Diagnostics) has launched its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.  The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure… Read More

#News

#Covid-19 #Drug approvals #FDA #Influenza #Rare disease

This week in drug discovery (19-23 September)

News round-up for 19-23 September by DDW Editor Reece Armstrong An interesting week for clinical research and drug approvals, with rare diseases being a key focus for both the FDA and European Commission. The last week has seen data emerge on how Omicron infection could protect against influenza, how… Read More

#News

Flu virus
#Covid-19 #Flu #Immune response #Influenza #Omicron

Omicron infection likely to protect against flu

The latest Omicron variants of Covid could be protective against serious influenza infection, a leading testing expert says. The milder variants have now made Covid-19 less dangerous than the flu, though there is still the risk of developing long Covid. Dr Quinton Fivelman PhD, Chief Scientific Officer at London Medical… Read More

#Covid-19 #News #Trending News